SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.NanoViricides is a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform…
Read More
About The Author
